Investment Thesis
Advanced Biomed exhibits strong profitability metrics (ROE 68.2%, ROA 59.6%) and exceptional liquidity (8.56x current ratio), but is severely constrained by negative operating cash flow of -1.1M and missing revenue data, indicating potential accounting or operational issues. The 17.1% YoY decline in net income coupled with deteriorating cash generation suggests underlying business challenges that fundamentals alone cannot fully explain.
ADVB Strengths
- Exceptional liquidity position with 8.56x current ratio and 2.6M cash reserves
- Very high ROE (68.2%) and ROA (59.6%) indicating efficient asset deployment
- Zero debt (0.00x Debt/Equity) with strong balance sheet structure (9.5M equity vs 1.4M liabilities)
- Positive net income of 6.5M demonstrates profitability in absolute terms
ADVB Risks
- Critical red flag: Missing revenue data prevents assessment of actual business performance and margin quality
- Negative operating cash flow (-1.1M) contradicts positive net income, suggesting aggressive accounting or non-cash revenues
- Declining earnings trend with 17.1% YoY net income decline and 14.3% EPS decline indicates deteriorating business momentum
- Data quality concerns with limited available metrics and missing standard income statement components (gross profit, margins)
- Zero insider activity in past 90 days raises concerns about management confidence in company trajectory
Key Metrics to Watch
- Operating cash flow recovery - critical to validate earnings quality and sustainability
- Revenue disclosure and composition - essential to understand if business is generating legitimate top-line growth
- Net income trend stabilization - monitor if 17.1% YoY decline continues or reverses
- Cash burn rate - track if negative OCF continues to erode the 2.6M cash position
ADVB Financial Metrics
ADVB Profitability Ratios
ADVB Balance Sheet & Liquidity
ADVB 5-Year Financial Trend
5-Year Trend Summary: Advanced Biomed Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.14 indicates the company is currently unprofitable.
ADVB Growth Metrics (YoY)
ADVB Capital Allocation
ADVB SEC Filings
Access official SEC EDGAR filings for Advanced Biomed Inc. (CIK: 0001941029)